{"transactions":[{"id":4636916,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-07T20:00:06.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":27.6968,"value":830904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be\nfurnished to the SEC staff upon request."}],"balance_after":782881,"source":{"system":"sec-edgar","filing":"0001193125-26-416950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526416950/ownership.xml","form_type":"4"}},{"id":4616750,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:09.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":2081,"price":33.0919,"value":68864.2439,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":278064,"source":{"system":"sec-edgar","filing":"0001193125-26-390510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390510/ownership.xml","form_type":"4"}},{"id":4616749,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:09.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":7947,"price":32.2139,"value":256003.8633,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":280145,"source":{"system":"sec-edgar","filing":"0001193125-26-390510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390510/ownership.xml","form_type":"4"}},{"id":4616752,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:08.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":1042,"price":33.2302,"value":34625.8684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be\nfurnished to the SEC staff upon request."}],"balance_after":233625,"source":{"system":"sec-edgar","filing":"0001193125-26-390509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390509/ownership.xml","form_type":"4"}},{"id":4616751,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:08.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":9768,"price":32.2681,"value":315194.8008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805  to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":234667,"source":{"system":"sec-edgar","filing":"0001193125-26-390509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390509/ownership.xml","form_type":"4"}},{"id":4616742,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:06.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":11,"price":33.34,"value":366.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":190838,"source":{"system":"sec-edgar","filing":"0001193125-26-390508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1913765/000119312526390508/ownership.xml","form_type":"4"}},{"id":4616741,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:06.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":9525,"price":32.4556,"value":309139.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":190849,"source":{"system":"sec-edgar","filing":"0001193125-26-390508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1913765/000119312526390508/ownership.xml","form_type":"4"}},{"id":4616744,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:05.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":1439,"price":33.1552,"value":47710.3328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.87 to $33.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3613056,"source":{"system":"sec-edgar","filing":"0001193125-26-390506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526390506/ownership.xml","form_type":"4"}},{"id":4616743,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:05.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":29025,"price":32.1293,"value":932552.9325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.81 to $32.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3614495,"source":{"system":"sec-edgar","filing":"0001193125-26-390506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526390506/ownership.xml","form_type":"4"}},{"id":4616746,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:03.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":919,"price":33.1488,"value":30463.7472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.855  to $33.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3613123,"source":{"system":"sec-edgar","filing":"0001193125-26-390507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526390507/ownership.xml","form_type":"4"}},{"id":4616745,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:03.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":29545,"price":32.1557,"value":950040.1565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.81 to $32.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3614042,"source":{"system":"sec-edgar","filing":"0001193125-26-390507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526390507/ownership.xml","form_type":"4"}},{"id":286,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-02T20:00:27.000Z","date":"2026-08-31","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-380152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1969821/000119312526380152/ownership.xml","form_type":"4"}},{"id":285,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-02T20:00:27.000Z","date":"2026-08-31","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.76,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-380152","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1969821/000119312526380152/ownership.xml","form_type":"4"}},{"id":284,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:00:27.000Z","date":"2026-08-31","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":5.05,"value":126250.0,"ownership":{"direct":true},"balance_after":116900,"source":{"system":"sec-edgar","filing":"0001193125-26-380152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1969821/000119312526380152/ownership.xml","form_type":"4"}},{"id":283,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:00:27.000Z","date":"2026-08-31","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":1.76,"value":44000.0,"ownership":{"direct":true},"balance_after":91900,"source":{"system":"sec-edgar","filing":"0001193125-26-380152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1969821/000119312526380152/ownership.xml","form_type":"4"}},{"id":679861,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:09.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":22807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":244435,"source":{"system":"sec-edgar","filing":"0001193125-26-359679","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359679/ownership.xml","form_type":"4"}},{"id":680063,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:07.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":60039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":3643520,"source":{"system":"sec-edgar","filing":"0001193125-26-359678","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526359678/ownership.xml","form_type":"4"}},{"id":679860,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:06.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":21284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":200374,"source":{"system":"sec-edgar","filing":"0001193125-26-359677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359677/ownership.xml","form_type":"4"}},{"id":679859,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:05.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":22807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":288092,"source":{"system":"sec-edgar","filing":"0001193125-26-359676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359676/ownership.xml","form_type":"4"}},{"id":680064,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:03.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":60039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":3643587,"source":{"system":"sec-edgar","filing":"0001193125-26-359675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526359675/ownership.xml","form_type":"4"}},{"id":710600,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:00:02.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":17.6081,"value":264121.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":179090,"source":{"system":"sec-edgar","filing":"0001193125-26-301996","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526301996/ownership.xml","form_type":"4"}},{"id":710599,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:00:02.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":18.3164,"value":274746.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":194090,"source":{"system":"sec-edgar","filing":"0001193125-26-301996","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526301996/ownership.xml","form_type":"4"}},{"id":746150,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:11.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261641","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526261641/ownership.xml","form_type":"4"}},{"id":746152,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":38806,"kind":"person","name":"Quimi Daphne","position":1,"cik":"0001543031","reported_name":"Quimi Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:09.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261640","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526261640/ownership.xml","form_type":"4"}},{"id":746625,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:06.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000119312526261638/ownership.xml","form_type":"4"}},{"id":746239,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:05.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000119312526261637/ownership.xml","form_type":"4"}},{"id":746488,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":38851,"kind":"person","name":"Zeiher Bernhardt G","position":1,"cik":"0001971421","reported_name":"Zeiher Bernhardt G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T16:00:20.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261647","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971421/000119312526261647/ownership.xml","form_type":"4"}},{"id":763718,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T20:00:07.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":3800,"price":13.51,"value":51338.0,"ownership":{"direct":true},"balance_after":66900,"source":{"system":"sec-edgar","filing":"0001193125-26-239216","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526239216/ownership.xml","form_type":"4"}},{"id":853786,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:10.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":373295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":373295,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":373295},"source":{"system":"sec-edgar","filing":"0001193125-26-098440","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526098440/ownership.xml","form_type":"4"}},{"id":853785,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:10.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":248865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3583548,"source":{"system":"sec-edgar","filing":"0001193125-26-098440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526098440/ownership.xml","form_type":"4"}},{"id":853499,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:08.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":111990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer\nthrough each such vesting date."}],"balance_after":111990,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":111990},"source":{"system":"sec-edgar","filing":"0001193125-26-098439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098439/ownership.xml","form_type":"4"}},{"id":853498,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:08.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":74660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":209090,"source":{"system":"sec-edgar","filing":"0001193125-26-098439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098439/ownership.xml","form_type":"4"}},{"id":853496,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-09T20:00:07.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":143985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":143985,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":143985},"source":{"system":"sec-edgar","filing":"0001193125-26-098438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098438/ownership.xml","form_type":"4"}},{"id":853495,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:07.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":95990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":261628,"source":{"system":"sec-edgar","filing":"0001193125-26-098438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098438/ownership.xml","form_type":"4"}},{"id":853784,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:05.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":373295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":373295,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":373295},"source":{"system":"sec-edgar","filing":"0001193125-26-098437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526098437/ownership.xml","form_type":"4"}},{"id":853783,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:05.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":248865,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3583481,"source":{"system":"sec-edgar","filing":"0001193125-26-098437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526098437/ownership.xml","form_type":"4"}},{"id":853494,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:03.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":143985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer\nthrough each such vesting date."}],"balance_after":143985,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":143985},"source":{"system":"sec-edgar","filing":"0001193125-26-098436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098436/ownership.xml","form_type":"4"}},{"id":853493,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:03.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":95990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting\nPerson's continued service to the Issuer through each such vesting date."}],"balance_after":265285,"source":{"system":"sec-edgar","filing":"0001193125-26-098436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098436/ownership.xml","form_type":"4"}},{"id":862077,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:13.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":29282,"price":14.4717,"value":423760.3194,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.360. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3334616,"source":{"system":"sec-edgar","filing":"0001193125-26-091443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526091443/ownership.xml","form_type":"4"}},{"id":862078,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:10.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":29282,"price":14.484,"value":424120.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.160. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3334683,"source":{"system":"sec-edgar","filing":"0001193125-26-091442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526091442/ownership.xml","form_type":"4"}},{"id":861574,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:07.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":6461,"price":14.5806,"value":94205.2566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":169295,"source":{"system":"sec-edgar","filing":"0001193125-26-091440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526091440/ownership.xml","form_type":"4"}},{"id":861573,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:04.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7909,"price":14.5216,"value":114851.3344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":165638,"source":{"system":"sec-edgar","filing":"0001193125-26-091438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526091438/ownership.xml","form_type":"4"}},{"id":861560,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:02.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":6844,"price":14.5205,"value":99378.302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.400 to $15.070. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":134430,"source":{"system":"sec-edgar","filing":"0001193125-26-091436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526091436/ownership.xml","form_type":"4"}},{"id":881958,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-25T21:00:03.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":3419,"price":14.1422,"value":48352.1818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.030 to $14.220.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":141274,"source":{"system":"sec-edgar","filing":"0001193125-26-071460","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526071460/ownership.xml","form_type":"4"}},{"id":919388,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:19.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":3557,"price":14.6463,"value":52096.8891,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.460 to $14.790.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":173547,"source":{"system":"sec-edgar","filing":"0001193125-26-037553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526037553/ownership.xml","form_type":"4"}},{"id":919626,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:16.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":15500,"price":14.6834,"value":227592.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3363965,"source":{"system":"sec-edgar","filing":"0001193125-26-037552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526037552/ownership.xml","form_type":"4"}},{"id":919387,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:11.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":3448,"price":14.6507,"value":50515.6136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.470 to $14.810.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":144693,"source":{"system":"sec-edgar","filing":"0001193125-26-037548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526037548/ownership.xml","form_type":"4"}},{"id":919625,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:08.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":15500,"price":14.685,"value":227617.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3363898,"source":{"system":"sec-edgar","filing":"0001193125-26-037544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526037544/ownership.xml","form_type":"4"}},{"id":935520,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":false,"shares":2818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":0,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":2818},"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935519,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":false,"shares":197182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":2818,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":197182},"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935518,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"sale","planned":false,"acquired":false,"shares":1974,"price":13.8293,"value":27299.0382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3379465,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935517,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":true,"shares":2818,"price":7.57,"value":21332.26,"ownership":{"direct":true},"balance_after":3381439,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935516,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":136193,"price":13.5895,"value":1850794.7735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3378621,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935515,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:27.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":true,"shares":197182,"price":7.57,"value":1492667.74,"ownership":{"direct":true},"balance_after":3514814,"source":{"system":"sec-edgar","filing":"0001193125-26-017057","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526017057/ownership.xml","form_type":"4"}},{"id":935526,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":false,"shares":2847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":0,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":2847},"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":935525,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":false,"shares":197153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. The option is due to expire on February 19, 2026."}],"balance_after":2847,"derivative":{"exercise_price":7.57,"expiration_date":"2026-02-19","underlying":"Common Stock","underlying_shares":197153},"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":935524,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-16","kind":"sale","planned":false,"acquired":false,"shares":1995,"price":13.8853,"value":27701.1735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3379398,"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":935523,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":true,"shares":2847,"price":7.57,"value":21551.79,"ownership":{"direct":true},"balance_after":3381393,"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":935522,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-15","kind":"sale","planned":false,"acquired":false,"shares":136193,"price":13.5827,"value":1849868.6611,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3378546,"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":935521,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-21T02:46:02.000Z","date":"2026-01-15","kind":"exercise","planned":false,"acquired":true,"shares":197153,"price":7.57,"value":1492448.21,"ownership":{"direct":true},"balance_after":3514739,"source":{"system":"sec-edgar","filing":"0001193125-26-017056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526017056/ownership.xml","form_type":"4"}},{"id":939364,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T21:08:37.000Z","date":"2026-01-12","kind":"gift","planned":false,"acquired":false,"shares":17780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift for no consideration."}],"balance_after":812881,"source":{"system":"sec-edgar","filing":"0001193125-26-012921","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000119312526012921/ownership.xml","form_type":"4"}},{"id":943203,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:05:17.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":3326,"price":11.1106,"value":36953.8556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.99 to $11.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":177104,"source":{"system":"sec-edgar","filing":"0001193125-26-007669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526007669/ownership.xml","form_type":"4"}},{"id":943366,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:05:12.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":7715,"price":11.0948,"value":85596.382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.05 to $11.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3317632,"source":{"system":"sec-edgar","filing":"0001193125-26-007666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312526007666/ownership.xml","form_type":"4"}},{"id":943364,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:05:08.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":7715,"price":11.0939,"value":85589.4385,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.99 to $11.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3317586,"source":{"system":"sec-edgar","filing":"0001193125-26-007664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312526007664/ownership.xml","form_type":"4"}},{"id":959597,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-24T01:48:33.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":8100,"price":12.45,"value":100845.0,"ownership":{"direct":true},"balance_after":63100,"source":{"system":"sec-edgar","filing":"0001193125-25-331289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525331289/ownership.xml","form_type":"4"}},{"id":981512,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-03T21:39:50.000Z","date":"2025-12-01","kind":"sale","planned":false,"acquired":false,"shares":6580,"price":14.3493,"value":94418.394,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.30 to $14.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":175756,"source":{"system":"sec-edgar","filing":"0001193125-25-306818","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525306818/ownership.xml","form_type":"4"}},{"id":1027588,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:16.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":200,"price":15.01,"value":3002.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325301,"source":{"system":"sec-edgar","filing":"0001193125-25-228343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312525228343/ownership.xml","form_type":"4"}},{"id":1027587,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:16.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":29775,"price":14.3728,"value":427950.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325501,"source":{"system":"sec-edgar","filing":"0001193125-25-228343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000119312525228343/ownership.xml","form_type":"4"}},{"id":1027182,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:13.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":8828,"price":14.5751,"value":128668.9828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":148141,"source":{"system":"sec-edgar","filing":"0001193125-25-228342","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525228342/ownership.xml","form_type":"4"}},{"id":1027181,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:12.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":10558,"price":14.6477,"value":154650.4166,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":280430,"source":{"system":"sec-edgar","filing":"0001193125-25-228341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525228341/ownership.xml","form_type":"4"}},{"id":1027590,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:10.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":200,"price":14.9975,"value":2999.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.995 to $15.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325347,"source":{"system":"sec-edgar","filing":"0001193125-25-228340","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312525228340/ownership.xml","form_type":"4"}},{"id":1027589,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:10.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":29733,"price":14.3433,"value":426469.3389,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3325547,"source":{"system":"sec-edgar","filing":"0001193125-25-228340","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000119312525228340/ownership.xml","form_type":"4"}},{"id":1027180,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:08.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":12039,"price":14.5791,"value":175517.7849,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":182336,"source":{"system":"sec-edgar","filing":"0001193125-25-228339","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525228339/ownership.xml","form_type":"4"}},{"id":1066419,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-08-14T20:20:11.000Z","date":"2025-08-13","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":8.3364,"value":125046.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":156969,"source":{"system":"sec-edgar","filing":"0000950170-25-108912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025108912/ownership.xml","form_type":"4"}},{"id":1066418,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-08-14T20:20:11.000Z","date":"2025-08-12","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":8.0735,"value":121102.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.82 to $8.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":171969,"source":{"system":"sec-edgar","filing":"0000950170-25-108912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025108912/ownership.xml","form_type":"4"}},{"id":1117974,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":27194,"kind":"person","name":"FONTEYNE PAUL R.","position":1,"cik":"0001727550","reported_name":"FONTEYNE PAUL R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:12:55.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727550/000095017025083734/ownership.xml","form_type":"4"}},{"id":1117866,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":260,"kind":"person","name":"Firestone Karen","position":1,"cik":"0001969821","reported_name":"Firestone Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:08:39.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025083719/ownership.xml","form_type":"4"}},{"id":1117865,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":38806,"kind":"person","name":"Quimi Daphne","position":1,"cik":"0001543031","reported_name":"Quimi Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:07:56.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025083717/ownership.xml","form_type":"4"}},{"id":1118352,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:06:38.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017025083713/ownership.xml","form_type":"4"}},{"id":1118273,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":38851,"kind":"person","name":"Zeiher Bernhardt G","position":1,"cik":"0001971421","reported_name":"Zeiher Bernhardt G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T16:06:03.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083709","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971421/000095017025083709/ownership.xml","form_type":"4"}},{"id":1133391,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-05-27T20:01:25.000Z","date":"2025-05-22","kind":"gift","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift for no consideration."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a bona fide gift for no consideration."}],"balance_after":186969,"source":{"system":"sec-edgar","filing":"0000950170-25-077677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025077677/ownership.xml","form_type":"4"}},{"id":1183409,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-02T21:22:59.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":10896,"price":3.4697,"value":37805.8512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":290988,"source":{"system":"sec-edgar","filing":"0000950170-25-049581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025049581/ownership.xml","form_type":"4"}},{"id":1183408,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-02T21:14:24.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":12425,"price":3.4674,"value":43082.445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":194375,"source":{"system":"sec-edgar","filing":"0000950170-25-049567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025049567/ownership.xml","form_type":"4"}},{"id":1183407,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-04-02T21:12:23.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":9192,"price":3.4763,"value":31954.1496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":187969,"source":{"system":"sec-edgar","filing":"0000950170-25-049560","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025049560/ownership.xml","form_type":"4"}},{"id":1183911,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-02T20:57:43.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":21490,"price":3.4659,"value":74482.191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.435 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3355280,"source":{"system":"sec-edgar","filing":"0000950170-25-049513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025049513/ownership.xml","form_type":"4"}},{"id":1183907,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-02T20:52:50.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":21490,"price":3.4646,"value":74454.254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3355276,"source":{"system":"sec-edgar","filing":"0000950170-25-049495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000095017025049495/ownership.xml","form_type":"4"}},{"id":1193740,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":38851,"kind":"person","name":"Zeiher Bernhardt G","position":1,"cik":"0001971421","reported_name":"Zeiher Bernhardt G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-24T16:15:37.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.7005,"value":37005.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.65 to $3.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-25-043849","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971421/000095017025043849/ownership.xml","form_type":"4"}},{"id":1215022,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-11T00:34:21.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":95777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":95777,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":95777},"source":{"system":"sec-edgar","filing":"0000950170-25-036717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036717/ownership.xml","form_type":"4"}},{"id":1215021,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:34:21.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":63851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":197161,"source":{"system":"sec-edgar","filing":"0000950170-25-036717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036717/ownership.xml","form_type":"4"}},{"id":1215018,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:32:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":102630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":102630,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":102630},"source":{"system":"sec-edgar","filing":"0000950170-25-036712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036712/ownership.xml","form_type":"4"}},{"id":1215017,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:32:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":68420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":206800,"source":{"system":"sec-edgar","filing":"0000950170-25-036712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036712/ownership.xml","form_type":"4"}},{"id":1215364,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-11T00:30:43.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":270177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":270177,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":270177},"source":{"system":"sec-edgar","filing":"0000950170-25-036711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000095017025036711/ownership.xml","form_type":"4"}},{"id":1215363,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:30:43.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":180118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3376766,"source":{"system":"sec-edgar","filing":"0000950170-25-036711","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000095017025036711/ownership.xml","form_type":"4"}},{"id":1215366,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:28:36.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":270177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":270177,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":270177},"source":{"system":"sec-edgar","filing":"0000950170-25-036708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025036708/ownership.xml","form_type":"4"}},{"id":1215365,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:28:36.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":180118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":3376770,"source":{"system":"sec-edgar","filing":"0000950170-25-036708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025036708/ownership.xml","form_type":"4"}},{"id":1215020,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-11T00:28:19.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":102630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":102630,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":102630},"source":{"system":"sec-edgar","filing":"0000950170-25-036707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036707/ownership.xml","form_type":"4"}},{"id":1215019,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:28:19.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":68420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":301884,"source":{"system":"sec-edgar","filing":"0000950170-25-036707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036707/ownership.xml","form_type":"4"}},{"id":1223047,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21282,"kind":"person","name":"Klee Justin B.","position":1,"cik":"0001898314","reported_name":"Klee Justin B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:35:19.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":4595,"price":3.152,"value":14483.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.10 to $3.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3196648,"source":{"system":"sec-edgar","filing":"0000950170-25-033725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898314/000095017025033725/ownership.xml","form_type":"4"}},{"id":1223048,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21283,"kind":"person","name":"Cohen Joshua B","position":1,"cik":"0001898644","reported_name":"Cohen Joshua B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:32:37.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":4595,"price":3.1663,"value":14549.1485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.09 to $3.195. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3196652,"source":{"system":"sec-edgar","filing":"0000950170-25-033719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898644/000095017025033719/ownership.xml","form_type":"4"}},{"id":1222390,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21223,"kind":"person","name":"Mazzariello Gina","position":1,"cik":"0001913765","reported_name":"Mazzariello Gina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:32:20.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":1611,"price":3.1175,"value":5022.2925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.10 to $3.165. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":133310,"source":{"system":"sec-edgar","filing":"0000950170-25-033717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025033717/ownership.xml","form_type":"4"}}],"next_cursor":"2025-03-05T21:32:20.000000Z,1222390"}